Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer) (MitoCardioFer)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03541213
Recruitment Status : Recruiting
First Posted : May 30, 2018
Last Update Posted : October 28, 2019
Sponsor:
Information provided by (Responsible Party):
University Hospital, Angers

Brief Summary:

Iron is involved in essential functions of the body. It allows the transport of oxygen in the blood, via hemoglobin, at the muscular level, via myoglobin, and it is also involved in cellular metabolism in general, in particular for the production of ATP at the mitochondrial level, within the cytochromes and iron-sulfur proteins of the respiratory chain.

Recently, iron deficiency has been identified as an important prognostic factor in heart failure patients. Iron therapy improves symptoms and physical performances of heart failure patients, even in the absence of anemia. As a result, the correction of iron deficiency is now proposed as one of the therapies for heart failure. However, the pathophysiology of the association between cardiac dysfunction and iron deficiency is still poorly understood.

The investigators previously developed a mouse model of iron deficiency without anemia, in which the investigators observed impaired physical performances, a decrease of left ventricular ejection fraction, and a decrease in mitochondrial complex I activity. These abnormalities were normalized after iron injection. These animal data suggest that iron deficiency is responsible for left ventricular dysfunction secondary to mitochondrial I complex abnormalities, and that iron therapy corrects them.

Iron deficiency is very common in the preoperative period of cardiac surgery, affecting 40 to 50% of patients. During this surgery, it is possible to perform a myocardial biopsy without risk to the patient.

The purpose of this study is to verify in patients requiring valvular heart surgery, if iron deficiency is responsible for a decrease in mitochondrial complex I activity and a decrease in cardiac function during the perioperative period, and to verify whether iron treatment improves these abnormalities.


Condition or disease Intervention/treatment Phase
Iron-deficiency Valvular Heart Disease Procedure: myocardial biopsy Procedure: sternal bone marrow biopsy Biological: blood sample Not Applicable

Detailed Description:

Iron is involved in essential functions of the body. It allows the transport of oxygen in the blood, via hemoglobin, at the muscular level, via myoglobin, and it is also involved in cellular metabolism in general, in particular for the production of ATP at the mitochondrial level, within the cytochromes and iron-sulfur proteins of the respiratory chain.

Iron deficiency has been shown to be responsible for fatigue and muscle weakness, regardless of the presence of an anemia. Recently, iron deficiency has been identified as an important prognostic factor in heart failure patients, with a prevalence increasing with NYHA class level, and association with mortality. Iron therapy improves the symptoms of heart failure patients and the 6-minute walk test, even in the absence of anemia. The correction of iron deficiency is now proposed as one of the therapies for heart failure. However, the pathophysiology of the association between cardiac dysfunction and iron deficiency is still poorly understood.

The investigators previously developed a mouse model of iron deficiency without anemia, in which the investigators observed impaired physical performances, a decrease of left ventricular ejection fraction, and a decrease in mitochondrial complex I activity. These abnormalities were normalized after iron injection. These animal data suggest that iron deficiency is responsible for left ventricular dysfunction secondary to mitochondrial I complex abnormalities, and that iron therapy corrects them.

Iron deficiency is very common in the preoperative period of cardiac surgery, affecting 40 to 50% of patients. During this surgery, it is possible to perform a myocardial biopsy without risk to the patient. There is therefore an opportunity to further explore the impact of iron deficiency and its treatment on mitochondrial energy metabolism of cardiomyocytes. We hypothesize that the activity of the mitochondrial complex I is decreased in the presence of iron deficiency and that the iron treatment corrects this decrease.

The purpose of this study is to verify in patients requiring valvular heart surgery, if iron deficiency is responsible for a decrease in mitochondrial complex I activity and a decrease in cardiac function during the perioperative period, and to verify whether iron treatment improves these abnormalities.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: 3 groups will be performed depending on the presence or absence of a pre-operative iron deficiency and whether they had an iron treatment preoperatively (before their inclusion in the study). However, patient management will not be different in the different groups from their inclusion in the study. Therefore we can consider that there is a single interventional group.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Impact de la Carence Martiale et de Son Traitement Sur le métabolisme Mitochondrial du Cardiomyocyte (MitoCardioFer)
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy Iron

Arm Intervention/treatment
Control group

Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.

Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)

Procedure: myocardial biopsy
Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.

Procedure: sternal bone marrow biopsy
Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores

Biological: blood sample
blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)

Iron deficiency group

Patients with iron deficiency who did not receive intravenous iron prior to inclusion.

Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)

Procedure: myocardial biopsy
Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.

Procedure: sternal bone marrow biopsy
Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores

Biological: blood sample
blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)

Iron treated group

Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).

Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)

Procedure: myocardial biopsy
Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.

Procedure: sternal bone marrow biopsy
Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores

Biological: blood sample
blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)




Primary Outcome Measures :
  1. Measure of the maximal activity of the mitochondrial complex I using spectrometry [ Time Frame: At the time of the myocardial biopsy ]
    Measure of the maximal complex I activity using spectrometry on isolated mitochondria from myocardial biopsy.


Secondary Outcome Measures :
  1. Measure of the maximal activity of the others mitochondrial complexes using spectrometry (Complexes II, III and IV) [ Time Frame: At the time of the myocardial biopsy ]
  2. Quantification of the number of mitochondria per cardiomyocyte using Western-Blot [ Time Frame: At the time of the myocardial biopsy ]
  3. Quantification and analysis of the complex I assemblage using BN-PAGE [ Time Frame: At the time of the myocardial biopsy ]
  4. Quantification of myoglobin in cardiomyocytes using Western-Blot [ Time Frame: At the time of the myocardial biopsy ]
  5. Cardiac function using echocardiography in pre-, intra- and post-operative periods [ Time Frame: At the time of the myocardial biopsy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Patients that must be operated for a valvular heart surgery (aortic or mitral) scheduled in the month which follows the anaesthesia consultation (visit of inclusion)
  • The preoperative iron status is known
  • Patient signed informed consent

Exclusion Criteria:

  • Refusal of the patient to participate
  • Refusal of the surgeon or the anaesthetist who are responsible of patient management
  • Patients with a known iron overload (for example : hemochromatosis)
  • Counter-indication in the realization of a sternal bone marrow biopsy or myocardial biopsy (for example : endocarditis)
  • Adult patients under legal guardianship
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03541213


Contacts
Layout table for location contacts
Contact: Emmanuel RINEAU, MD 0(33)2 41 35 36 35 Emmanuel.Rineau@chu-angers.fr
Contact: Sigismond Lasocki, PU-PH 0(33)2 41 35 36 35 ext 33 SiLasocki@chu-angers.fr

Locations
Layout table for location information
France
CHU Angers - DEPARTEMENT D'ANESTHESIE REANIMATION Recruiting
Angers, France, 49100
Contact: Emmanuel Rineau, MD         
Sponsors and Collaborators
University Hospital, Angers
Investigators
Layout table for investigator information
Principal Investigator: RINEAU Emmanuel, MD University Hospital
Layout table for additonal information
Responsible Party: University Hospital, Angers
ClinicalTrials.gov Identifier: NCT03541213    
Other Study ID Numbers: 2017-A00904-49
First Posted: May 30, 2018    Key Record Dates
Last Update Posted: October 28, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Angers:
ferric carboxymaltose
mitochondrial metabolism
cardiomyocyte
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Heart Valve Diseases
Anemia, Iron-Deficiency
Cardiovascular Diseases
Anemia, Hypochromic
Anemia
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases